A recent study from NYU Langone Health indicates that men genetically predisposed to androgenetic alopecia may face a 7% increased risk of hair loss when using GLP-1 drugs such as Ozempic, Wegovy, and Zepbound. This finding suggests that hair thinning may not solely result from…
Recent research indicates that semaglutide, a drug used for weight loss, may also extend lifespan and improve health measures in elderly mice. While the findings are intriguing, t…
A recent NIH-funded study indicates that semaglutide, a key ingredient in GLP-1 drugs like Ozempic, may extend lifespan and improve various health markers in older mice. The resea…
A recent review published in the International Journal of Molecular Sciences examines over 126 studies on berberine, highlighting its effects on gut inflammation, the intestinal b…
A recent analysis published in the Journal of the Endocrine Society suggests that visceral fat, rather than aging, plays a more significant role in lowering testosterone levels in…
A recent study indicates that semaglutide, a GLP-1 drug commonly used for weight loss, may extend lifespan and improve health markers in elderly mice, mimicking the effects of cal…
Recent studies indicate that GLP-1 obesity injections, including Ozempic and Mounjaro, may not be effective for all individuals, with some participants failing to achieve signific…
A recent review published in the International Journal of Molecular Sciences examines the effects of berberine on metabolism, revealing that its impact is more nuanced than often…
Recent research presented at the Endocrine Society’s ENDO 2026 meeting reveals that individuals taking GLP-1 weight loss medications, such as Ozempic and Wegovy, not only lost wei…
Naomi Pineiro, a 33-year-old from Puerto Rico, was misdiagnosed with Type 2 diabetes after routine blood work showed elevated glucose levels. Despite maintaining an active lifesty…
This article explores how GLP-1 medications, such as semaglutide, may influence emotional states and motivation, potentially leading to a phenomenon described as 'Ozempic personal…
A recent study published in the Journal of Investigative Dermatology suggests that GLP-1 drugs, commonly used for weight loss and diabetes management, may increase the risk of hai…
Beauty industry leaders are ramping up efforts to develop treatments specifically designed for those experiencing facial volume loss, promising to redefine the standards of beauty…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…
In a stunning twist of regulatory fate, the FDA has issued new hair-raising guidelines for users of GLP-1 drugs like Ozempic and Mounjaro, warning of a 37-68% increased risk of ha…